The objective of this study was to assess effectiveness and safety of Depo-Provera (medroxyprogesterone acetate) in treatment of endometrial hyperplasia (EH) and to compare it with norethisterone acetate (NETA) as an oral progestogen treatment. One hundred forty six women aged 35 to 50 years with abnormal uterine bleeding and diagnosed as having EH were randomized to receive either Depo-Provera, one injection every 3 months for 6 months (2 doses), or oral cyclic NETA, 15 mg daily for 14 days per cycle for 6 months. Primary outcome measure was regression of EH. Secondary outcome variables were side effects of treatment, persistence/progression of EH during follow-up period. After 6 months of treatment, Depo-Provera was more successful in achieving regression of nonatypical EH than NETA (67 [91.8%] of 73 women vs 49 [67.1%] of 73, respectively), and the difference between the 2 groups was statistically significant (relative risk: 1.37; 95% confidence interval: 1.15-1.63, P = .048*). Adverse effects were relatively common with moderate differences between the 2 groups. This is the first randomized study comparing Depo-Provera with an oral progestogen as a treatment for EH. Depo-Provera is an effective and safe treatment for EH without atypia.
EppleinMReedSDVoigtLFNewtonKWHoltVLWeissNS. Endometrial hyperplasia risk in relation to characteristics and exposures that influence endogenous hormone levels. Am J Epidemiol. 2008;168(6):563–570.
2.
ReedSDVoigtLFNewtonKM. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol. 2009;113(3):655–662.
3.
EspindolaDKennedyKAFischerEG. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet Gynecol Clin North Am. 2007;34(4):717–737.
4.
AnastasiadisPGSkaphidaPGKoutlakiNGGalaziosGCTsikourasPNLiberisVA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000;21(2):131–134.
5.
LaceyJVJrChiaVM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63(1):39–44.
6.
MarsdenDEHackerNF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol. 2001;15(3):393–405.
7.
GundersonCCFaderANCarsonKABristowRE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–482.
8.
GultekinMDoganNUAksanGOzgulN. Management of endometrial hyperplasia. Minerva Ginecol. 2010;62(5):433–445.
9.
EddibAAllafBLeeJYehJ. Risk for advanced-stage endometrial cancer in surgical specimens from patients with complex endometrial hyperplasia with atypia. Gynecol Obstet Invest. 2012;73(1):38–42.
10.
ClarkTJNeelakantanDGuptaJK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol. 2006;125(2):259–264.
11.
TrimbleCLKaudererJZainoR. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812–819.
12.
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106(2):413–425.
13.
Abu-HashimHZayedAGhayatyEEl RakhawyM. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol. 2013;24(2):128–134.
14.
HornLCSchnurrbuschUBilekKHentschelBEinenkelJ. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14(2):348–353.
15.
ØrboAVereideABArnesMPettersenIStraumeB. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014;121(4):477–486.
16.
BeseTVuralAOzturkM. The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer. 2006;16(2):809–813.
17.
WesthoffC. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68(2):75–87.
National Institute for Health and Care Excellence. Long-acting reversible contraception. NICE guidelines [CG30] October 2005. http://www.nice.org.uk/guidance/cg30. Accessed December 15, 2015.
20.
El BeheryMMSalehHSIbrahiemMAKamalEMKassemGAMohamed MohamedME. Levonorgestrel-Releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015;22(3):329–334.
21.
VereideABArnesMStraumeBMaltauJMOrboA. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003;91(3):526–533.
22.
GallosIDKrishanPShehmarMGanesanRGuptaJK. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod. 2013;28(5):1231–1236.
23.
ButtiniMJJordanSJWebbPM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol. 2009;49(3):316–322.
24.
SchragerS. Abnormal uterine bleeding associated with hormonal contraception. Am Fam Physician. 2002;65(10):2073–2081.
25.
HaoulaZJWalkerKFPowellMC. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):176–179.
26.
GallosIDShehmarMThangaratinamSPapapostolouTKCoomarasamyAGuptaJK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.e1-e10.
27.
DemirkiranFYavuzEErenelHBeseTArvasMSaniogluC. Which is the best technique for endometrial sampling? Aspiration (pipelle) versus dilatation and curettage (D&C). Arch Gynecol Obstet. 2012;286(5):1277–1282.
28.
ZainoRJKaudererJTrimbleCL. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106:804–811.
29.
GallosIDOfinranOShehmarMCoomarasamyAGuptaJK. Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):305–307.
